Austin Asset Management Co Inc Reduces Position in Eli Lilly and Company $LLY

Austin Asset Management Co Inc cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,685 shares of the company’s stock after selling 49 shares during the quarter. Eli Lilly and Company makes up approximately 0.6% of Austin Asset Management Co Inc’s portfolio, making the stock its 20th largest holding. Austin Asset Management Co Inc’s holdings in Eli Lilly and Company were worth $2,873,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. WestEnd Advisors LLC increased its position in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company in the first quarter worth approximately $27,000. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. bought a new position in shares of Eli Lilly and Company in the first quarter worth approximately $40,000. Finally, TD Capital Management LLC increased its position in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $845.55 on Thursday. The stock has a fifty day moving average of $738.69 and a 200 day moving average of $766.57. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The firm has a market capitalization of $800.28 billion, a price-to-earnings ratio of 55.26, a PEG ratio of 1.18 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm posted $3.92 earnings per share. The firm’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the topic of a number of recent research reports. JPMorgan Chase & Co. reduced their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, September 16th. Cantor Fitzgerald reduced their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $943.00.

Insider Buying and Selling at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.